|
|
News Breaks
|
October 6, 2009
|
| 08:09 EDT |  | PTIE |
| theflyonthewall.com: | Pain Therapeutics Remoxy still in-line to be first to market, says Gabelli | | Gabelli still believes that Pain Therapeutics' (PTIE) Remoxy will be the first long-acting oxycodone with abuse deterrent features to be approved with a differentiated label. The firm thinks that Purdue Pharmaceutical's Oxycotin, a potential competitor, will have to undergo much more scrutiny by the FDA. The firm maintains a Buy rating on Pain Therapeutics. :theflyonthewall.com |
|
|
News For PTIE From The Last 14 Days Check below for free stories on PTIE the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 9, 2012
|
| 09:06 EDT |  | PTIE |
| theflyonthewall.com: | Pain Therapeutics reports Q4 EPS (1c) vs. consensus (2c) | | Reports revenue $2.75M vs. consensus $2.97M. :theflyonthewall.com |
|
|
|
|
|
